Download Full Text (526 KB)

Presentation date

Summer 8-10-2022

College, Institute, or Department

Pharmaceutical Sciences

Faculty Mentor

Joseph A. Vetro

Research Mentor

Stephen M. Curran


Nano- and microparticles are used in the pharmaceutical industry for sustained release drug delivery systems. For example, polymeric particles are currently used as an FDA-approved drug delivery system for leuprolide acetate to treat prostate cancer1. Our drug of interest is CPDI-02 (formerly known as EP67)—a C5a-derived decapeptide agonist of the C5a Receptor (CD88) that activates mononuclear phagocytes to produce an immune response while potentially minimizing neutrophil-mediated toxicity2. Currently in the Vetro Lab, CPDI-02 is being tested on pigs and mice to treat methicillin-resistant Staphylococcus aureus (MRSA) infections and as the adjuvant for a vaccine for cytomegalovirus (CMV). This investigation explored formulation parameters that impact particle size and loading of CPDI-02 in a traditional oil-in-water (O/W) emulsion. We also explored adapting the formulation using microfluidic chips to generate nano- and microparticles and improve run-to-run consistency in particle size.


Micro- Nanoparticles

The Formation and Application of Polymeric Micro- and Nanoparticles